MEASUREMENT STARTING POINTS
Company Baselines
Sourced facts needed to measure a catalyst from a declared starting point. These records are not earnings summaries, forecasts, impact findings or grades.
Baseline standard
Relevant · every fact connects to a defined measurement question.
Dated · the baseline and each reported period remain visible.
Sourced · each fact links to its primary evidence.
Labeled · reported facts and N-Ledger calculations remain distinct.
PUBLISHED BASELINES
Measurement records
Science · Biotech · MRNA · baseline Oct 5, 2026
Moderna, Inc.
Moderna: Can Phase 3 Intismeran Success Convert Personalized mRNA Cancer Therapy Into a Scalable Oncology Franchise?October 5, 2026 evidence baseline for the August 19 Phase 3 interim topline. Later October 7 and October 13 developments remain separately dated in the thesis. Detailed efficacy, regulatory filing, commercial supply and attributable profit are not established. Four stars measures potential significance; there is no initial outcome or Depth grade. FY2028 annual review and two comparable postlaunch quarters are the author's fixed adjudication and persistence rules.
| Measurement | Starting fact | Why it matters | Evidence |
|---|---|---|---|
| Phase 3 interim RFS and DMFS | MetAugust 19, 2026 topline · Company-reported topline | Direction established; numerical Phase 3 efficacy and absolute benefit remain undisclosed. | Source ↗ |
| Intismeran net collaboration expense | $97M USDQ2 2026 · Reported GAAP program-wide expense | Program-wide net expense, not melanoma-only cost or profit. | Source ↗ |
| Intismeran net collaboration expense | $198M USDH1 2026 · Reported GAAP program-wide expense | Six-month program-wide net expense, not a quarterly or commercial profit measure. | Source ↗ |
Public readers can inspect baseline facts for public research. Individual, Professional, Business and Enterprise clients receive company baselines across their applicable coverage.